Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Comorbidities in patients with myasthenia gravis in the USA: a retrospective claims database analysis
Autoimmune Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
6-003
Patients with myasthenia gravis (MG) often have comorbidities that contribute to their overall disease burden. These comorbidities can be at risk of exacerbation due to the conventional treatments prescribed for MG.
To characterize the comorbidity burden in patients with MG in the USA.
This US retrospective observational cohort study utilized de-identified patient data (from 01/01/2006–06/30/2019) from the IQVIA insurance claims database. Eligible patients were ≥ 18 years old; had ≥ 2 claims (≥ 30 days apart) with MG diagnoses ICD9 or ICD10 codes; and had ≥ 1 year of continuous enrollment before and after MG diagnosis. Extracted data included demographic and clinical characteristics, comorbidities, treatment history and follow-up. The prevalence of comorbidities for the overall population and by conventional MG therapies were also assessed.

Data for 3,516 patients with MG were identified (51.2% male; mean age [standard deviation], 55.8 [13.9]; age range, 18–84 years). The most prevalent comorbidities were cardiovascular and endocrine disorders, including hypertension (41.9%), hyperlipidemia (37.1%), fatigue (24.8%), uncomplicated diabetes (18.2%), cerebrovascular disease (17.6%) and hypothyroidism (15.4%). Chronic pulmonary disease (13.5%) and sleep disorders (13.2%) were also common comorbidities. Patients were often prescribed conventional MG therapies, which have the potential exacerbate their comorbid conditions. Within 1 year prior to initiation of corticosteroids, 42.7%, 18.6% and 8.6% of patients were diagnosed with hypertension, uncomplicated diabetes and osteoporosis, respectively. Similarly, 6.5% of patients prescribed chronic intravenous immunoglobulin and 14.3% of patients prescribed azathioprine were diagnosed with venous thromboembolism and malignancy, respectively, within 1 year prior to treatment initiation. 

This study demonstrates the high rates of comorbidities in patients with MG and the importance of considering the potential impact of these comorbidities in treatment choice discussions. 
Authors/Disclosures
Raj Bandaru (Astrazeneca Pharmaceuticals)
PRESENTER
Mr. Bandaru has received personal compensation for serving as an employee of Alexion Pharmaceuticals.
Daniel Basoff, PharmD, RPh (Alexion) Dr. Basoff has received personal compensation for serving as an employee of Alexion Pharmaceuticals.
Anju Parthan Anju Parthan has received personal compensation for serving as an employee of Alexion. Anju Parthan has received personal compensation for serving as an employee of Alkermes. Anju Parthan has received stock or an ownership interest from Alexion.
Anusorn Thanataveerat, Other (Aetion) Dr. Thanataveerat has received personal compensation for serving as an employee of Genesis Research. Dr. Thanataveerat has received personal compensation for serving as an employee of Aetion.
Matthew Kent Mr. Kent has nothing to disclose.
Michael K. Hehir, II, MD (Larner College of Medicine at the University of Vermont) Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Hehir has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Hehir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Hehir has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum- American Academy of Neurology. Dr. Hehir has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. The institution of Dr. Hehir has received research support from Myasthenia Gravis Foundation of America. The institution of Dr. Hehir has received research support from University of Vermont Medical Center.
Ali A. Habib, MD (University of California, Irvine) Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Immune Sciences. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from VielaBio. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Genentech. The institution of Dr. Habib has received research support from Regeneron.